A groundbreaking machine designed to extend the viability of donated lungs is set to significantly enhance transplantation rates across England and Wales. Currently, a staggering number of donated lungs—up to 80%—are discarded, leaving many patients waiting in vain for a life-saving transplant. With the backing of the National Institute for Health and Care Excellence (NICE), the XVIVO perfusion system could be a game-changer in addressing the chronic shortage of usable organs.
Addressing the Transplant Crisis
In the UK, lung transplantation statistics are alarmingly low compared to other developed nations. According to NHS Blood and Transplant, there are currently 170 individuals awaiting lung transplants, including six children. The stark reality is that many patients endure prolonged waits—often over a year—before receiving an organ, and tragically, up to 20% of adults on the transplant list may not survive the wait.
Factors contributing to this crisis include not only the quality of the donated organs but also systemic issues like staffing shortages and theatre capacity, resulting in a mere 23% of donated lungs being utilised. The XVIVO system aims to directly tackle these challenges by ensuring that more lungs remain viable for transplantation, potentially unlocking hundreds of organs that would otherwise go to waste.
How the XVIVO System Works
The XVIVO perfusion system operates by warming donated lungs to body temperature and circulating a fluid that mimics blood plasma. This innovative method also ventilates the organs, simulating normal breathing conditions. As a result, medical teams can monitor lung functionality, address infections, and manage other complications in real time.
Though the device has already undergone trials at several adult transplant centres, NICE’s recent draft guidance is a significant endorsement, recommending its use across all transplant facilities for an initial four-year assessment period. This move aims to standardise access to advanced organ preservation technology, irrespective of the centre’s size or location.
Expert Opinions on the New Technology
Dr Anastasia Chalkidou, NICE’s healthtech programme director, emphasised the importance of maximising every donated lung, stating, “Every donated lung is a precious gift, and right now too many of them never reach a patient who needs them.” She believes that this technology could provide transplant teams with crucial information and time to evaluate organs that might otherwise be discarded.
Jonathan Blades, head of policy at Asthma + Lung UK, echoed this sentiment, highlighting the need for renewed political and research focus on lung health in the UK. “This new technology marks an important step towards transforming lung health,” he stated, adding that it could provide more time for patients with serious conditions to spend with their loved ones, while also reducing the waste of viable organs.
Prof Andrew Fisher, a consultant transplant physician and member of the British Transplantation Society, called for robust evidence to demonstrate the machine’s impact on lung transplant activity. “It’s essential that we support timely access to transplants for patients desperately waiting for suitable organs,” he remarked.
Why it Matters
The introduction of the XVIVO perfusion system represents a significant leap forward in the fight against organ shortages in the UK. By improving the viability of donated lungs, this technology not only has the potential to save lives but also to transform the landscape of lung transplantation. As the nation grapples with one of the lowest lung transplant rates in Europe, innovations like this could pave the way for a future where every donated organ finds its way to a deserving patient, ensuring that no gift of life goes unappreciated.
